Quantitative Fracture Risk Reduction with Estrogen-Progesterone Therapy
Estrogen-progesterone hormone replacement therapy reduces overall fracture risk by approximately 24% (total fractures), with a 27% reduction in nonvertebral fractures, 34% reduction in hip fractures, and 40% reduction in vertebral fractures in postmenopausal women. 1, 2
Specific Fracture Risk Reductions
The most robust data comes from the Women's Health Initiative (WHI) trial and meta-analyses reviewed by the U.S. Preventive Services Task Force:
Overall Fracture Reduction
- Total fractures: 24% reduction (RH 0.76; 95% CI 0.63-0.92) 1, 2
- This represents a statistically significant benefit across all fracture types combined
Site-Specific Reductions
Hip Fractures:
- 34% reduction (RH 0.66; 95% CI 0.33-1.33) 1, 2
- Though this showed a trend toward benefit, it did not reach statistical significance in adjusted WHI analyses
- Observational studies show current users have a 36% reduction (RR 0.64; 95% CI 0.32-1.04) 1
Vertebral Fractures:
- 34% reduction (RH 0.66; 95% CI 0.32-1.34) 1, 2
- 40% reduction in observational studies for ever-users (RR 0.6; 95% CI 0.36-0.99) 1
Nonvertebral Fractures:
Wrist Fractures:
- 61% reduction in current users (RR 0.39; 95% CI 0.24-0.64) 1
Critical Context: Why This Matters But Isn't Recommended
The Evidence Quality
The fracture reduction data is considered "good to fair quality evidence" by USPSTF guidelines 1, 2. The WHI trial provides the highest quality randomized controlled trial data, though hip and vertebral fracture reductions did not achieve statistical significance individually—only total fractures did.
The Clinical Dilemma
Despite these impressive fracture reductions, the 2017 American College of Physicians guidelines explicitly recommend AGAINST using menopausal estrogen therapy or estrogen-plus-progestogen for osteoporosis treatment (Grade: strong recommendation; moderate-quality evidence) 3. This is because:
- Breast cancer risk increases by 26% (RH 1.26; 95% CI 1.00-1.59) 1
- Stroke risk increases
- Thromboembolic events increase
- The overall risk-benefit ratio is unfavorable when considering morbidity and mortality outcomes
When the Numbers Actually Apply
The fracture benefits are most pronounced in:
Women under 60 years or within 10 years of menopause: The benefit-risk ratio is more favorable in this window 4
Women with premature menopause: HRT is the primary therapy for bone protection in this population 5
Women with bothersome menopausal symptoms: If treating symptoms anyway, the bone protection is a secondary benefit 4
The Bone Density Effect
Beyond fractures, HRT increases bone mineral density by 3.7% at the hip after 3 years compared to 0.14% in placebo groups 6. This effect occurs at the hip, lumbar spine, and peripheral sites 1, 2.
Important Caveats
The protection only lasts while on therapy: After discontinuation, bone loss resumes at normal postmenopausal rates (approximately 1% per year) 1, 7. However, some studies suggest limited HRT use (2-3 years) in early menopause may provide long-lasting benefits with continued fracture risk reduction years after stopping 7.
The HERS trial contradiction: In women with established heart disease (secondary prevention population), combined estrogen-progestin showed NO reduction in fractures (RH 1.04; 95% CI 0.87-1.25) 1, 2. This highlights that the benefit may not apply universally to all postmenopausal women, particularly those with significant comorbidities.
Age matters: The fracture reduction appears most effective in women who start HRT within 5 years of menopause and continue it, with diminishing benefits in older women (≥60 years) 8, 9.